



PRESS RELEASE

AMOEBA announces its implantation in Canada and signs a letter of intent with the MAGNUS group

Lyon, Montreal June 3rd 2015 - AMOEBA, producer of a biological biocide capable of eliminating 100% of the bacterial risk in water, announced today that it has signed a letter of intent prior to a definitive agreement relating to the exclusive distribution of its product by the **MAGNUS** group throughout Canadian territory for a 5-year period, provided market authorisation (MA) is awarded for Canada, which could take place at the end of 2017.

AMOEBA's solution, which is still in its test phase, acts as a predator against bacteria that proliferate in water (legionella, pseudomonas, listeria, etc.). This product is 100% natural, it does not generate by-products presenting toxicity for humans or the environment. Thus, no waste-water treatment will be necessary for companies choosing to use this alternative technology.

Already, several companies such as Häagen-Dazs, ST Microelectronics and ArcelorMittal have used **AMOEBA's** biocide on an experimental basis and have shown its effectiveness on their industrial sites during the test phase.

*"We are particularly happy to have signed this letter of intent with **MAGNUS**. If it leads to a definitive agreement, it will provide us with access to the whole Canadian market, as soon as market authorisation has been acquired. **MAGNUS** is strongly committed to providing ecological solutions, which corresponds perfectly with our product's fundamental characteristics."* declares **Fabrice Plasson, President of AMOEBA's Board of Directors**.

*"When the various test phases are validated, **AMOEBA's** ecological solution would be an alternative technology for the future. We are delighted with this partnership which will allow us to offer our clients an innovation which has already proven its utility in large companies during the test phases."* indicates **Denis Pichet, President and CEO of MAGNUS**.

About AMOEBA:

Based in Lyon - France, **AMOEBA** develops a biological biocide capable of eliminating 100% of waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is an alternative to the traditionally used chemical treatments in the water treatment industry.



Commercialisation of this solution remains subject to the MA acquisition, which could be completed in the 1st quarter of 2016 for France and at the end of 2016 for the rest of Europe. In a worldwide market of chemical biocides, estimated to be worth 21 bn€⁽¹⁾, **AMOÉBA** is currently concentrating its activities on the segment of industrial air-cooled towers (ACT), estimated at 1.7 bn€⁽²⁾. Its breakthrough technology complies with new regulations in terms of environmental chemical emissions. For more information: www.amoeba-biocide.com

(1): Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2): Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

About MAGNUS:

Established in Canada since 1946, **MAGNUS** is an expert, ensuring the performance of various water treatment programmes for industrial, institutional and commercial applications. Strongly engaged in sustainable development, **MAGNUS** employs more than 125 people over 3 sites in Canada. Its multidisciplinary team - composed of several chemistry, microbiology and engineering specialists - along with state-of-the-art products, allows it to provide and personalise unique and powerful solutions for its customer base.

Active in a market directly affected by new environmental requirements, **MAGNUS** is recognised as a market leader in green chemistry and was awarded several prizes for its ongoing work in sustainable development. www.magnus.ca

Press contact:

Charlène MASSON

ACTIFIN

Telephone: +33(0)1 5688 1128

cmasson@actifin.fr